The Filings Report

Thermo Fisher Scientific

TMONYSECIK 97745Technology / Electronic Components & Instrumentsfiscal year ends December73 quarters since 2008

Revenue, Q2 FY2026
$12.0B
+10.5% on Q2 FY2025
Net income
$1.7B
+7.4% on Q2 FY2025
Free cash flow
$1.7B
+51.6% on Q2 FY2025
Diluted EPS
$4.68
+9.3% on Q2 FY2025
Revenue, TTM
$46.3B
trailing four quarters
Net margin, TTM
15.0%
net income $7.0B
Free cash flow, TTM
$7.3B
$9.0B less $1.7B capex
Cash and equivalents
$4.1B
long-term debt $42.3B, Jun 27, 2026
Shares, 12-month change
−2.1%
370M shares, Jun 27, 2026
Buybacks, TTM
$5.0B
1.9% of market value
Dividends, TTM
$662M
0.3% of market value
Market value
$257.7B
at the close, buybacks

Latest quarter Q2 FY2026, filed July 31, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 27, 2026, Thermo Fisher Scientific reported revenue of $12.0B, +10.5% on Q2 FY2025, and net income of $1.7B (+7.4%). Operating margin was 17.4%. Free cash flow, operating cash flow less capital expenditures, was $1.7B ($2.1B less $450M). Diluted earnings per share were $4.68.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of July 31, 2026.

Revenue and net incomeRevenueNet income
$0$5B$10B$15BQ3'22, Revenue: $10.7BQ3'22Q4'22, Revenue: $11.4BQ4'22Q1'23, Revenue: $10.7BQ1'23Q2'23, Revenue: $10.7BQ2'23Q3'23, Revenue: $10.6BQ3'23Q4'23, Revenue: $10.9BQ4'23Q1'24, Revenue: $10.3BQ1'24Q2'24, Revenue: $10.5BQ2'24, Net income: $1.5BQ2'24Q3'24, Revenue: $10.6BQ3'24, Net income: $1.6BQ3'24Q4'24, Revenue: $11.4BQ4'24, Net income: $1.8BQ4'24Q1'25, Revenue: $10.4BQ1'25, Net income: $1.5BQ1'25Q2'25, Revenue: $10.9BQ2'25, Net income: $1.6BQ2'25Q3'25, Revenue: $11.1BQ3'25, Net income: $1.6BQ3'25Q4'25, Revenue: $12.2BQ4'25, Net income: $2.0BQ4'25Q1'26, Revenue: $11.0BQ1'26, Net income: $1.7BQ1'26Q2'26, Revenue: $12.0BQ2'26, Net income: $1.7BQ2'26$0$5B$10B$15BQ3'22, Revenue: $10.7BQ4'22, Revenue: $11.4BQ4'22Q1'23, Revenue: $10.7BQ2'23, Revenue: $10.7BQ2'23Q3'23, Revenue: $10.6BQ4'23, Revenue: $10.9BQ4'23Q1'24, Revenue: $10.3BQ2'24, Revenue: $10.5BQ2'24, Net income: $1.5BQ2'24Q3'24, Revenue: $10.6BQ3'24, Net income: $1.6BQ4'24, Revenue: $11.4BQ4'24, Net income: $1.8BQ4'24Q1'25, Revenue: $10.4BQ1'25, Net income: $1.5BQ2'25, Revenue: $10.9BQ2'25, Net income: $1.6BQ2'25Q3'25, Revenue: $11.1BQ3'25, Net income: $1.6BQ4'25, Revenue: $12.2BQ4'25, Net income: $2.0BQ4'25Q1'26, Revenue: $11.0BQ1'26, Net income: $1.7BQ2'26, Revenue: $12.0BQ2'26, Net income: $1.7BQ2'26

Net income losses drawn in red.

Free cash flow
$0$1B$2B$3B$4BQ3'22, Free cash flow: $1.4BQ3'22Q4'22, Free cash flow: $2.9BQ4'22Q1'23, Free cash flow: $271MQ1'23Q2'23, Free cash flow: $1.3BQ2'23Q3'23, Free cash flow: $2.1BQ3'23Q4'23, Free cash flow: $3.3BQ4'23Q1'24, Free cash flow: $904MQ1'24Q2'24, Free cash flow: $1.7BQ2'24Q3'24, Free cash flow: $1.9BQ3'24Q4'24, Free cash flow: $2.8BQ4'24Q1'25, Free cash flow: $361MQ1'25Q2'25, Free cash flow: $1.1BQ2'25Q3'25, Free cash flow: $1.8BQ3'25Q4'25, Free cash flow: $3.0BQ4'25Q1'26, Free cash flow: $816MQ1'26Q2'26, Free cash flow: $1.7BQ2'26$0$1B$2B$3B$4BQ3'22, Free cash flow: $1.4BQ4'22, Free cash flow: $2.9BQ4'22Q1'23, Free cash flow: $271MQ2'23, Free cash flow: $1.3BQ2'23Q3'23, Free cash flow: $2.1BQ4'23, Free cash flow: $3.3BQ4'23Q1'24, Free cash flow: $904MQ2'24, Free cash flow: $1.7BQ2'24Q3'24, Free cash flow: $1.9BQ4'24, Free cash flow: $2.8BQ4'24Q1'25, Free cash flow: $361MQ2'25, Free cash flow: $1.1BQ2'25Q3'25, Free cash flow: $1.8BQ4'25, Free cash flow: $3.0BQ4'25Q1'26, Free cash flow: $816MQ2'26, Free cash flow: $1.7BQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$20B$40B$60BQ3'22, Cash and equivalents: $2.9BQ3'22, Long-term debt: $28.9BQ3'22Q4'22, Cash and equivalents: $8.5BQ4'22, Long-term debt: $34.3BQ4'22Q1'23, Cash and equivalents: $3.5BQ1'23, Long-term debt: $35.1BQ1'23Q2'23, Cash and equivalents: $3.1BQ2'23, Long-term debt: $33.8BQ2'23Q3'23, Cash and equivalents: $6.2BQ3'23, Long-term debt: $35.1BQ3'23Q4'23, Cash and equivalents: $8.1BQ4'23, Long-term debt: $34.7BQ4'23Q1'24, Cash and equivalents: $5.5BQ1'24, Long-term debt: $35.4BQ1'24Q2'24, Cash and equivalents: $7.1BQ2'24, Long-term debt: $35.2BQ2'24Q3'24, Cash and equivalents: $4.6BQ3'24, Long-term debt: $35.1BQ3'24Q4'24, Cash and equivalents: $4.0BQ4'24, Long-term debt: $31.1BQ4'24Q1'25, Cash and equivalents: $4.1BQ1'25, Long-term debt: $34.0BQ1'25Q2'25, Cash and equivalents: $4.6BQ2'25, Long-term debt: $35.0BQ2'25Q3'25, Cash and equivalents: $2.0BQ3'25, Long-term debt: $35.5BQ3'25Q4'25, Cash and equivalents: $9.9BQ4'25, Long-term debt: $39.2BQ4'25Q1'26, Cash and equivalents: $3.3BQ1'26, Long-term debt: $42.9BQ1'26Q2'26, Cash and equivalents: $4.1BQ2'26, Long-term debt: $42.3BQ2'26$0$20B$40B$60BQ3'22, Cash and equivalents: $2.9BQ3'22, Long-term debt: $28.9BQ4'22, Cash and equivalents: $8.5BQ4'22, Long-term debt: $34.3BQ4'22Q1'23, Cash and equivalents: $3.5BQ1'23, Long-term debt: $35.1BQ2'23, Cash and equivalents: $3.1BQ2'23, Long-term debt: $33.8BQ2'23Q3'23, Cash and equivalents: $6.2BQ3'23, Long-term debt: $35.1BQ4'23, Cash and equivalents: $8.1BQ4'23, Long-term debt: $34.7BQ4'23Q1'24, Cash and equivalents: $5.5BQ1'24, Long-term debt: $35.4BQ2'24, Cash and equivalents: $7.1BQ2'24, Long-term debt: $35.2BQ2'24Q3'24, Cash and equivalents: $4.6BQ3'24, Long-term debt: $35.1BQ4'24, Cash and equivalents: $4.0BQ4'24, Long-term debt: $31.1BQ4'24Q1'25, Cash and equivalents: $4.1BQ1'25, Long-term debt: $34.0BQ2'25, Cash and equivalents: $4.6BQ2'25, Long-term debt: $35.0BQ2'25Q3'25, Cash and equivalents: $2.0BQ3'25, Long-term debt: $35.5BQ4'25, Cash and equivalents: $9.9BQ4'25, Long-term debt: $39.2BQ4'25Q1'26, Cash and equivalents: $3.3BQ1'26, Long-term debt: $42.9BQ2'26, Cash and equivalents: $4.1BQ2'26, Long-term debt: $42.3BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed July 31, 2026.

Thermo Fisher Scientific income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 27, 2026filed Jul 31, 2026Q1 FY2026ended Mar 28, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 27, 2025filed Oct 31, 2025Q2 FY2025ended Jun 28, 2025filed Aug 1, 2025Q1 FY2025ended Mar 29, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025Q3 FY2024ended Sep 28, 2024filed Nov 1, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue11,99411,00512,21511,12210,85510,36411,39510,598+10.5%
Cost of revenue—————————
Gross profit—————————
Research and development364336356346352342374346+3.4%
Selling, general and administrative2,3332,1812,3522,1622,1402,0782,2032,098+9.0%
Operating income2,0871,8632,2551,9411,8341,7162,0161,838+13.8%
Other income (expense)31(9)6(2)(19)314(16)+263.2%
Pretax income1,9241,7342,1531,8261,7091,6201,9411,742+12.6%
Income tax16770153207929515099+81.5%
Net income1,7361,6511,9641,6161,6171,5071,8301,630+7.4%
Diluted EPS ($)4.684.43—4.274.283.98—4.25+9.3%
Diluted shares (millions)371373—378378379—384—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed July 31, 2026.

Thermo Fisher Scientific balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 27, 2026filed Jul 31, 2026Q1 FY2026ended Mar 28, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 27, 2025filed Oct 31, 2025Q2 FY2025ended Jun 28, 2025filed Aug 1, 2025Q1 FY2025ended Mar 29, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025Q3 FY2024ended Sep 28, 2024filed Nov 1, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents4,0643,2549,8521,9824,5764,1344,0094,645−11.2%
Short-term investments022531,5641,8141,8131,5612,000−100.0%
Total current assets23,36522,31628,70722,29524,58423,37822,13723,783−5.0%
Total assets113,174113,281110,343103,020101,23099,04197,321100,364+11.8%
Total current liabilities15,06914,62115,18914,88812,71813,17413,33214,601+18.5%
Long-term debt42,28442,94739,17235,48435,03333,98931,07235,113+20.7%
Total liabilities—————————
Stockholders’ equity52,67951,93453,40751,01850,51249,39049,58448,992+4.3%
Shares outstanding (millions)370372371376378377377383—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed July 31, 2026.

Thermo Fisher Scientific cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 27, 2026filed Jul 31, 2026Q1 FY2026ended Mar 28, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 27, 2025filed Oct 31, 2025Q2 FY2025ended Jun 28, 2025filed Aug 1, 2025Q1 FY2025ended Mar 29, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 20, 2025Q3 FY2024ended Sep 28, 2024filed Nov 1, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow2,1251,1923,4572,2391,3997233,2902,166+51.9%
Capital expenditures450376465404294362480272+53.1%
Free cash flow (CFO − capex)1,6758162,9921,8351,1053612,8101,894+51.6%
Depreciation and amortization—————————
Share repurchases1,0003,0003796302,0001,0000—
Dividends paid175162162163162149149150+8.0%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

Thermo Fisher Scientific income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Jul 31, 2009FY2007ended Dec 31, 2007filed Jul 31, 2009
Revenue44,55642,87942,85744,91539,21132,21825,54224,35820,91818,27416,96516,89013,09012,51011,55910,3939,91210,4989,746
Cost of revenue———————————————————
Gross profit———————————————————
Research and development1,3971,3901,3371,4711,4061,1811,003967887754692691396376340284———
Selling, general and administrative8,7328,5958,4458,9938,0076,9306,1446,0575,5044,9714,6124,8963,4463,3553,1072,7292,5932,6922,549
Operating income7,7467,3376,8598,39310,0287,7944,5943,7832,9602,4582,3362,5031,6101,4821,2511,1881,0021,229974
Other income (expense)(12)12(65)(104)(694)(76)(70)9(20)(13)(16)16(56)431(28)(20)4—
Pretax income7,3087,0376,2987,8358,8417,2304,0723,2622,4292,0241,9362,0871,3201,2691,1331,088880——
Income tax5476572847031,109850374324201(1)(44)19240111091025715394
Net income6,7046,3355,995—————————1,2731,1781,3301,036850981748
Diluted EPS ($)17.7416.5315.4517.6319.4615.969.177.245.595.094.924.713.483.213.462.532.012.251.69
Diluted shares (millions)378383388394397399403406398397402402366367385409423435444

Balance sheet

Thermo Fisher Scientific balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Jul 31, 2009FY2007ended Dec 31, 2007filed Jul 31, 2009
Cash and equivalents9,8524,0098,0778,5244,47710,3252,3992,1031,3357864521,3445,8268061,0169171,5641,281625
Short-term investments2531,5613————————9544978—
Total current assets28,70722,13724,58925,22920,11321,95711,89310,6259,4217,0215,7416,5409,8814,8354,8224,1354,5314,346—
Total assets110,34397,32198,72697,15495,12369,05258,38156,23256,66945,90840,83442,85231,86327,44526,83421,34921,62521,090—
Total current liabilities15,18913,33214,01217,01013,43610,3046,1976,1477,0484,8664,1465,3503,1262,0933,1131,7101,6391,540—
Long-term debt39,17231,07234,72734,27834,67021,72817,07617,719———————————
Total liabilities———————————————————
Stockholders’ equity53,40749,58446,73543,97840,79334,50729,67527,58625,41321,54021,35020,54816,85615,46515,03815,36115,43114,92714,464
Shares outstanding (millions)371377381385391394399399402390396397392358366391409——

Cash flow statement

Thermo Fisher Scientific cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 20, 2025FY2023ended Dec 31, 2023filed Feb 22, 2024FY2022ended Dec 31, 2022filed Feb 23, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 25, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Feb 28, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Feb 26, 2015FY2013ended Dec 31, 2013filed Feb 27, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 29, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Jul 31, 2009FY2007ended Dec 31, 2007filed Jul 31, 2009
Operating cash flow7,8188,6678,4069,1549,3128,2894,9734,5434,0053,2582,9422,6202,0112,0401,6911,4981,6591,4201,484
Capital expenditures1,5251,4001,4792,2432,5231,474926758508444423428282315261245200264176
Free cash flow (CFO − capex)6,2937,2676,9276,9116,7896,8154,0473,7853,4972,8142,5192,1921,7281,7241,4301,2521,4591,1561,308
Depreciation and amortization———————2,2672,0331,7581,6881,6851,000984860740763793757
Share repurchases3,0004,0003,0003,0002,0001,5001,5005007501,2505000901,1501,3381,013415187898
Dividends paid6365835234553953372972662372382412352161420————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$63M
93 sales by 5 insiders; officers and directors $63M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$146M
144 sales by 7 insiders; officers and directors $146M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 28, 2026Sperling Scott MDirectorgift3,490$0.00—65,989Oct 30, 2026
Oct 28, 2026Britt Lisa P.Sr. VP and Chief HR Officeropen-market sale2,831$706.45$2M11,560Oct 30, 2026
Aug 31, 2026Pettiti GianlucaPresident & COOopen-market sale10b5-1400$614.38$246K23,216Sep 1, 2026
Aug 31, 2026Pettiti GianlucaPresident & COOoption exercise3,733$309.63$1M26,949Sep 1, 2026
Aug 31, 2026Pettiti GianlucaPresident & COOopen-market sale10b5-13,733$614.38$2M23,216Sep 1, 2026
Aug 28, 2026Casper Marc NChairman & CEO, Directortax withholding725$622.18$451K123,201Sep 1, 2026
Aug 28, 2026Casper Marc NChairman & CEO, Directortax withholding532$622.18$331K122,669Sep 1, 2026
Aug 28, 2026Meyer JamesSr. Vice President & CFOtax withholding37$622.18$23K5,793Sep 1, 2026
Aug 28, 2026Meyer JamesSr. Vice President & CFOtax withholding44$622.18$28K5,748Sep 1, 2026
Aug 28, 2026Meyer JamesSr. Vice President & CFOtax withholding20$622.18$12K5,729Sep 1, 2026
Aug 28, 2026Meyer JamesSr. Vice President & CFOtax withholding55$622.18$34K5,673Sep 1, 2026
Aug 28, 2026Meyer JamesSr. Vice President & CFOtax withholding114$622.18$71K5,560Sep 1, 2026
Aug 28, 2026Shropshire Thomas B Jr.SVP and General Counseltax withholding49$622.18$31K6,009Sep 1, 2026
Aug 28, 2026Shafer Michael DExecutive Vice Presidenttax withholding162$622.18$101K20,832Sep 1, 2026
Aug 28, 2026Shafer Michael DExecutive Vice Presidenttax withholding211$622.18$131K20,621Sep 1, 2026
Aug 28, 2026Shafer Michael DExecutive Vice Presidenttax withholding190$622.18$118K20,431Sep 1, 2026
Aug 28, 2026Shafer Michael DExecutive Vice Presidenttax withholding227$622.18$141K20,204Sep 1, 2026
Aug 28, 2026Holmes Joseph R.VP & Chief Accounting Officertax withholding11$622.18$7K2,956Sep 1, 2026
Aug 28, 2026Holmes Joseph R.VP & Chief Accounting Officertax withholding13$622.18$8K2,943Sep 1, 2026
Aug 28, 2026Holmes Joseph R.VP & Chief Accounting Officertax withholding11$622.18$7K2,931Sep 1, 2026
Aug 28, 2026Holmes Joseph R.VP & Chief Accounting Officertax withholding15$622.18$9K2,916Sep 1, 2026
Aug 28, 2026Pettiti GianlucaPresident & COOtax withholding212$622.18$132K24,439Sep 1, 2026
Aug 28, 2026Pettiti GianlucaPresident & COOtax withholding304$622.18$189K24,135Sep 1, 2026
Aug 28, 2026Pettiti GianlucaPresident & COOtax withholding249$622.18$155K23,886Sep 1, 2026
Aug 28, 2026Pettiti GianlucaPresident & COOtax withholding270$622.18$168K23,616Sep 1, 2026

Full insider history for Thermo Fisher Scientific, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

2 of the tracked managers held TMO in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded TMO by quarter.

FundManagerQuarterValueSharesWeightMove
Duquesne Family OfficeStanley DruckenmillerQ2 2026$10M19,2000.18%new
Baron Capital GroupRon BaronQ2 2026$5M9,2190.01%trimmed −61.1%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
THERMO FISHER SCIENTIFIC INC., CIK 97745 on EDGAR
Extract generated
August 27, 2026
Withheld
2 line-years whose four quarters do not sum to the filed year: revenue FY2009, revenue FY2010
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: not filed
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: not filed
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/TMO.json